Cargando…

Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome

BACKGROUND: Treat-to-target therapy approaches are established for chronic diseases such as diabetes, hypertension, and more recently rheumatoid arthritis, resulting in improved patient outcomes. These approaches do not use patient reported outcomes (PRO) as targets of therapy. Chronic spontaneous u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lima, Hermenio, Gooderham, Melinda, Dutz, Jan, Lynde, Charles, Chapdelaine, Hugo, Ellis, Anne, Gilbert, Martin, Ho, Vincent, Papp, Kim, Poulin, Yves, Sussman, Gordon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569543/ https://www.ncbi.nlm.nih.gov/pubmed/28852410 http://dx.doi.org/10.1186/s13223-017-0210-0

Ejemplares similares

The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from ASSURE‐CSU
por: Maurer, M., et al.
Publicado: (2017)

Omalizumab in chronic spontaneous urticaria (CSU): experience in three cases
por: Valle, Solange Oliveira Rodrigues, et al.
Publicado: (2015)

Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE‐CSU
por: Sussman, G., et al.
Publicado: (2018)

ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria
por: Weller, Karsten, et al.
Publicado: (2015)

Clinical Remission of Chronic Spontaneous Urticaria (CSU): A Targeted Literature Review
por: Balp, Maria-Magdalena, et al.
Publicado: (2021)

Increased serum free IgE levels in patients with chronic spontaneous urticaria (CSU)()
por: Jang, Jae-Hyuk, et al.
Publicado: (2022)

Insights and advances in chronic urticaria: a Canadian perspective
por: Sussman, Gordon, et al.
Publicado: (2015)

Advances in Understanding and Managing Chronic Urticaria
por: Moolani, Yasmin, et al.
Publicado: (2016)

Effects of Vaccination against COVID-19 in Chronic Spontaneous and Inducible Urticaria (CSU/CIU) Patients: A Monocentric Study
por: Grieco, Teresa, et al.
Publicado: (2022)

Type I and type IIb autoimmune chronic spontaneous urticaria: Using common clinical tools for endotyping patients with CSU
por: Sella, Juliana A., et al.
Publicado: (2023)

O10 - Rupatadine is effective and safe in the treatment of Chronic Spontaneous Urticaria (CSU) in pediatric patients (2-11 years old)
por: Potter, Paul, et al.
Publicado: (2014)

Suppression of Basophil FcεRI Activation by Serum from Active Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Subjects
por: Sterba, Patricia M, et al.
Publicado: (2015)

Psoriasis Prevalence and Severity by Expert Elicitation
por: Papp, Kim A., et al.
Publicado: (2021)

Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology
por: Papp, Kim A., et al.
Publicado: (2021)

Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review
por: Wong, Melanie Mitsui, et al.
Publicado: (2020)

Definition of Recurrent Chronic Spontaneous Urticaria
por: MELÉ-NINOT, Gemma, et al.
Publicado: (2020)

Urticaria relapse after mRNA COVID‐19 vaccines in patients affected by chronic spontaneous urticaria and treated with antihistamines plus omalizumab: A single‐center experience
por: Picone, Vincenzo, et al.
Publicado: (2022)

Neutral Dietary Effects of Two MicroRNAs, Csu-Novel-260 and Csu-Mir-14, on the Non-Target Arthropod Folsomia candida
por: Zhou, Qinli, et al.
Publicado: (2023)

Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2022)

Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2023)

COVID-19 Vaccine Induced Flares of Chronic Spontaneous Urticaria: A Case Series
por: Smee, Madeleine, et al.
Publicado: (2022)

35181 Baseline disease and population characteristics associated with a diagnosis of COVID 19: Data from the PURE registry
por: Albrecht, Lorne, et al.
Publicado: (2022)

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Pathophysiology of bradykinin and histamine mediated angioedema
por: Lima, Hermenio, et al.
Publicado: (2023)

Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
por: Asero, Riccardo, et al.
Publicado: (2023)

Resource Use and Costs in an Insured Population of Patients with Chronic Idiopathic/Spontaneous Urticaria
por: Broder, Michael S., et al.
Publicado: (2015)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

Hyperresponsiveness to antihistamines in spontaneous urticaria and heat urticaria
por: Durda, J., et al.
Publicado: (2017)

In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria
por: Moñino‐Romero, Sherezade, et al.
Publicado: (2023)

Chronic Spontaneous Urticaria Triggered by the AstraZeneca/Oxford COVID-19 Vaccine with Achieved Remission: A Case Report
por: Brooks, Stephanie G, et al.
Publicado: (2022)

Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study
por: Hollis, Kelly, et al.
Publicado: (2018)

Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2023)

Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2023)

Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria
por: Kolkhir, Pavel, et al.
Publicado: (2021)

Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
por: Forgie, Jennifer, et al.
Publicado: (2014)

Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria()
por: Metz, Martin, et al.
Publicado: (2022)

35158 Adaptations in the PURE registry in response to the COVID 19 pandemic: The impact of well-designed modifications in real-world data collection in a psoriasis registry
por: Lynde, Charles, et al.
Publicado: (2022)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Treatment of Chronic Spontaneous Urticaria
por: Kaplan, Allen P.
Publicado: (2012)

What Basophil Testing Tells Us About CSU Patients – Results of the CORSA Study
por: Marcelino, João, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aest20l71p8ja1a4ule25fp0ps